

Ref. No: 2568  
Date: 14/05/26  
Subject: Derm and Rheum New Patients

## REQUEST & RESPONSE

Q1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]	<5	
Adalimumab [All Biosimilars]	44	
Apremilast [Otezla]	<5	
Apremilast [Generic]	0	
Etanercept [Enbrel]	0	
Etanercept [All Biosimilars]	0	
Infliximab [Remicade]	0	
Infliximab [All Biosimilars]	0	
Ustekinumab [Stelara]	0	
Ustekinumab [All Biosimilars]	6	
Bimekizumab [Bimzelx]	<5	
Brodalumab [Kyntheum]	0	
Certolizumab [Cimzia]	0	
Deucravacitinib [Sotyktu]	0	
Dimethyl Fumarate [Skilarence]	0	
Guselkumab [Tremfya]	9	
Ixekizumab [Taltz]	9	

Risankizumab [Skyrizi]	25	
Secukinumab [Cosentyx]	11	
Spesolimab [Spevigo]	0	
Tildrakizumab [Ilumetri]	0	

Q2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]	<5			
Adalimumab [Humira]	0			
Adalimumab [All Biosimilars]	65			
Apremilast [Otezla]	0			
Apremilast [Generic]	0			
Baricitinib [Olumiant]	<5			
Bimekizumab [Bimzelx]	<5			
Certolizumab [Cimzia]	<5			
Etanercept [Enbrel]	0			
Etanercept [All Biosimilars]	7			
Filgotinib [Jyseleca]	1			
Golimumab [Simponi]	0			
Golimumab [All Biosimilars]	0			
Guselkumab [Tremfya]	0			
Infliximab [Remicade]	0			
Infliximab [All Biosimilars]	0			

Ixekizumab [Taltz]	0			
Risankizumab [Skyrizi]	0			
Rituximab [MabThera]	0			
Rituximab [Biosimilars]	0			
Sarilumab [Kevzara]	0			
Secukinumab [Cosentyx]	12			
Tocilizumab [RoActemra]	<5			
Tocilizumab [Biosimilars]	<5			
Tofacitinib [Xeljanz]	<5			
Upadacitinib [Rinvoq]	0			
Ustekinumab [Stelara]	0			
Ustekinumab Biosimilar	0			